Page last updated: 2024-11-12

tetracosapentaenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetracosapentaenoic acid: RN given refers to (all-Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tetracosapentaenoic acid : A polyunsaturated fatty acid whose structure contains double bonds at any five positions of a 24-carbon straight chain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID20839348
MeSH IDM0261949

Synonyms (5)

Synonym
81276-12-2
tetracosapentaenoic acid, (all-z)-
(all-z)-tetracosapentaenoic acid
tetracosapentaenoic acid
(2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (30.00)18.2507
2000's3 (30.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.43 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]